These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 16251235

  • 1. Effect of pravastatin in people with diabetes and chronic kidney disease.
    Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C, Pfeffer M, Simes J, Isles C, Furberg C, West M, Craven T, Curhan G.
    J Am Soc Nephrol; 2005 Dec; 16(12):3748-54. PubMed ID: 16251235
    [Abstract] [Full Text] [Related]

  • 2. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, Craven T, West M.
    Circulation; 2004 Sep 21; 110(12):1557-63. PubMed ID: 15364796
    [Abstract] [Full Text] [Related]

  • 3. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease.
    Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, Simes J, West M, Packard C, Curhan GC.
    Circulation; 2005 Jul 12; 112(2):171-8. PubMed ID: 15998677
    [Abstract] [Full Text] [Related]

  • 4. Undiagnosed renal impairment in patients with and without diabetes with normal serum creatinine undergoing percutaneous coronary intervention.
    Bachorzewska-Gajewska H, Malyszko J, Malyszko JS, Musial W, Dobrzycki S.
    Nephrology (Carlton); 2006 Dec 12; 11(6):549-54. PubMed ID: 17199796
    [Abstract] [Full Text] [Related]

  • 5. Chronic kidney disease and cardiovascular risk in hypertensive type 2 diabetics: a primary care perspective.
    Ravera M, Noberasco G, Re M, Filippi A, Gallina AM, Weiss U, Cannavò R, Ravera G, Cricelli C, Deferrari G.
    Nephrol Dial Transplant; 2009 May 12; 24(5):1528-33. PubMed ID: 19073656
    [Abstract] [Full Text] [Related]

  • 6. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease.
    Vlagopoulos PT, Tighiouart H, Weiner DE, Griffith J, Pettitt D, Salem DN, Levey AS, Sarnak MJ.
    J Am Soc Nephrol; 2005 Nov 12; 16(11):3403-10. PubMed ID: 16162813
    [Abstract] [Full Text] [Related]

  • 7. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999.
    Foley RN, Murray AM, Li S, Herzog CA, McBean AM, Eggers PW, Collins AJ.
    J Am Soc Nephrol; 2005 Feb 12; 16(2):489-95. PubMed ID: 15590763
    [Abstract] [Full Text] [Related]

  • 8. Impact of gender on statin efficacy.
    Dale KM, Coleman CI, Shah SA, Patel AA, Kluger J, White CM.
    Curr Med Res Opin; 2007 Mar 12; 23(3):565-74. PubMed ID: 17355737
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
    Asselbergs FW, Diercks GF, Hillege HL, van Boven AJ, Janssen WM, Voors AA, de Zeeuw D, de Jong PE, van Veldhuisen DJ, van Gilst WH, Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators.
    Circulation; 2004 Nov 02; 110(18):2809-16. PubMed ID: 15492322
    [Abstract] [Full Text] [Related]

  • 11. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP, ALLIANCE Investigators.
    Am J Kidney Dis; 2009 May 02; 53(5):741-50. PubMed ID: 19216014
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular and renal outcome in subjects with K/DOQI stage 1-3 chronic kidney disease: the importance of urinary albumin excretion.
    Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT, PREVEND Study Group.
    Nephrol Dial Transplant; 2008 Dec 02; 23(12):3851-8. PubMed ID: 18641082
    [Abstract] [Full Text] [Related]

  • 13. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
    Whitfield MD, Gillett M, Holmes M, Ogden E.
    Public Health; 2006 Dec 02; 120(12):1140-8. PubMed ID: 17084425
    [Abstract] [Full Text] [Related]

  • 14. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.
    Nephrol Dial Transplant; 2009 May 02; 24(5):1663-71. PubMed ID: 19145003
    [Abstract] [Full Text] [Related]

  • 15. [Does statin therapy reduce the risk of stroke? A meta-analysis].
    Sirol M, Bouzamondo A, Sanchez P, Lechat P.
    Ann Med Interne (Paris); 2001 Apr 02; 152(3):188-93. PubMed ID: 11431579
    [Abstract] [Full Text] [Related]

  • 16. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Charlton-Menys V, DeMicco DA, Fuller JH, CARDS Investigators.
    Am J Kidney Dis; 2009 Nov 02; 54(5):810-9. PubMed ID: 19540640
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Metabolic syndrome is not a risk factor for kidney dysfunction in obese non-diabetic subjects.
    Gatti A, Morini E, De Cosmo S, Maiani F, Mandosi E, Fallarino M, Morano S, Trischitta V.
    Obesity (Silver Spring); 2008 Apr 02; 16(4):899-901. PubMed ID: 18239564
    [Abstract] [Full Text] [Related]

  • 19. The impact of diabetes mellitus on the prognostic value of a normal dobutamine stress echocardiogram in patients with intermediate to high cardiovascular risk.
    Low AF, Ng WL, Lim YT, Yeo TC.
    Singapore Med J; 2004 Apr 02; 45(4):161-5. PubMed ID: 15094984
    [Abstract] [Full Text] [Related]

  • 20. The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study.
    Atthobari J, Brantsma AH, Gansevoort RT, Visser ST, Asselbergs FW, van Gilst WH, de Jong PE, de Jong-van den Berg LT, PREVEND study group.
    Nephrol Dial Transplant; 2006 Nov 02; 21(11):3106-14. PubMed ID: 16720593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.